跳至主要内容
临床试验/NCT00610012
NCT00610012已完成不适用

Clinical Registry Describing Treatment Reality and Therapy Modality of Patients With Metastatic or Locally Advanced Renal Cell Carcinoma Requiring Therapy

iOMEDICO AG1 个研究点 分布在 1 个国家目标入组 1,500 人开始时间: 2007年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
iOMEDICO AG
入组人数
1,500
试验地点
1
主要终点
Documentation of therapies

研究概览

简要总结

The purpose of this registry is to record information of therapy reality of metastatic or locally advanced Renal Cell Carcinoma by office-based medical oncologists in Germany.

详细描述

The RCC Registry is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with mRCC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with metastatic or locally advanced Renal Cell Carcinoma requiring therapy
  • Start of first palliative therapy within 1 year before enrollment of patient to registry; since enrollment of 1000 Patients: start of first palliative therapy within 4 weeks before enrollment

排除标准

  • 未提供

结局指标

主要结局

Documentation of therapies

时间窗: 9 years, 3 years per patient

次要结局

  • Documentation of response rate and adverse reactions; development of a numeric prognostic score(9 years)

研究者

发起方
iOMEDICO AG
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验